AVA 201
Alternative Names: AVA-201 - Avalon GloboCare; Mesenchymal stem cells derived EVs-miR-185; MSC-EV-miR-185; MSC-Exo-miR185Latest Information Update: 28 Aug 2023
At a glance
- Originator Avalon GloboCare
- Class Antineoplastics; Exosome therapies; Immunotherapies; MicroRNAs
- Mechanism of Action NF-kappa B inhibitors; Proto-oncogene protein c-akt inhibitors; RNA interference; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Leucoplakia; Mouth neoplasm
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for preclinical development in Leucoplakia in USA (Topical)
- 28 Aug 2023 No recent reports of development identified for preclinical development in Mouth-neoplasm in USA (Topical)
- 15 Jul 2019 Preclinical trials in Leucoplakia in USA (Topical) prior to July 2019